SELLAS Life Sciences Group, Inc. (SLS) Stock

SELLAS Life Sciences Group, Inc. is an advanced biopharmaceutical company specializing in the development of cutting-edge cancer immunotherapies across various indications within the United States. At the forefront of its portfolio is galinpepimut-S (GPS), a novel cancer immunotherapeutic targeting Wilms tumor 1. GPS is currently advancing through Phase III clinical trials for the treatment of acute myeloid leukemia and is also under investigation in Phase 1/2 trials for ovarian cancer treatment. Additionally, SELLAS Life Sciences Group is developing nelipepimut-S, another cancer immunotherapy targeting human epidermal growth factor receptor 2, currently in Phase 2b clinical trials for early-stage breast cancer.

Strategically, the company has entered into a collaboration with Merck & Co., Inc. to explore the combination of GPS with the PD1 blocker pembrolizumab. This partnership aims to evaluate GPS across multiple cancer types, including hematologic malignancies and solid tumors, in a Phase 1/2 clinical trial. SELLAS Life Sciences Group, founded in 2012 and headquartered in New York, New York, continues to drive advancements in cancer immunotherapy with a focus on enhancing treatment outcomes and expanding therapeutic options for patients worldwide.

With a robust pipeline and strategic collaborations, SELLAS Life Sciences Group remains dedicated to pioneering transformative therapies that harness the power of the immune system to combat cancer effectively. The company's innovative approach underscores its commitment to addressing unmet medical needs and improving the lives of individuals facing challenging oncological conditions.